Skip to main content

Advertisement

SpringerLink
Log in

Gestione clinica del paziente con iperparatiroidismo primario non candidabile alla paratiroidectomia

  • PARATIROIDI E MEN
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Bilezikian JP, Cusano NE, Khan AA et al. (2016) Primary hyperparathyroidism. Nat Rev Dis Primers 2:16033

    Article  Google Scholar 

  2. Wermers R, Clarke B (2015) Epidemiology of primary hyperparathyroidism. In: Bilezikian J, Marcus R, Levine MA et al. (eds) The parathyroids, 3rd edn. Elsevier, Amsterdam, pp 297–308

    Chapter  Google Scholar 

  3. Bilezikian JP, Brandi ML, Eastell R et al. (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569

    Article  CAS  Google Scholar 

  4. Prezioso D, Strazzullo P, Lotti T et al. (2015) Dietary treatment of urinary risk factors for renal stone formation. A review of CLU working group. Arch Ital Urol Androl 87(2):105–120

    Article  CAS  Google Scholar 

  5. Marcocci C, Bollerslev J, Khan AA, Shoback DM (2014) Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 99(10):3607–3618

    Article  CAS  Google Scholar 

  6. Ross AC, Taylor CL, Yaktine AL et al. (2011) Dietary reference intakes for calcium and vitamin D. Academies Press, Washington

    Google Scholar 

  7. Lee JH, Kim JH, Hong AR et al. (2017) Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism. Osteoporos Int 28(5):1667–1674

    Article  CAS  Google Scholar 

  8. Rolighed L, Rejnmark L, Sikjaer T et al. (2014) Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab 99(3):1072–1080

    Article  CAS  Google Scholar 

  9. Peacock M, Bilezikian JP, Klassen PS et al. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90(1):135–141

    Article  CAS  Google Scholar 

  10. Silverberg SJ, Rubin MR, Faiman C et al. (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92(10):3803–3808

    Article  CAS  Google Scholar 

  11. Makras P, Anastasilakis AD (2018) Bone disease in primary hyperparathyroidism. Metabolism 80:57–65

    Article  CAS  Google Scholar 

  12. Vitale C, Bermond F, Rodofili A et al. (2016) Effetti del Cinacalcet sulla biochimica urinaria e il rischio litogeno in pazienti con iperparatiroidismo primitivo e calcolosi renale. G Ital Nefrol 33(4):gin/33.4.7

    PubMed  Google Scholar 

  13. Brardi S, Cevenini G, Verdacchi T et al. (2015) Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch Ital Urol Androl 87(1):66–71

    Article  CAS  Google Scholar 

  14. Khan AA, Bilezikian JP, Kung AW et al. (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89(7):3319–3325

    Article  CAS  Google Scholar 

  15. Faggiano A, Di Somma C, Ramundo V et al. (2011) Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 39(3):283–287

    Article  CAS  Google Scholar 

  16. Grey AB, Stapleton JP, Evans MC et al. (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360–368

    Article  CAS  Google Scholar 

  17. Leere JS, Karmisholt J, Robaczyk M et al. (2020) Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 8(5):407–417

    Article  CAS  Google Scholar 

  18. Zanchetta JR, Bogado CE (2001) Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 16:189–190

    Article  CAS  Google Scholar 

  19. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88:1174–1178

    Article  CAS  Google Scholar 

  20. Moor MB, Bonny O (2016) Ways of calcium reabsorption in the kidney. Am J Physiol, Ren Physiol 310(11):F1337–1350

    Article  CAS  Google Scholar 

  21. Tsvetov G, Hirsch D, Shimon I et al. (2017) Thiazide treatment in primary hyperparathyroidism – a new indication for an old medication? J Clin Endocrinol Metab 102(4):1270–1276

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. U.O. Endocrinologia, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italia

    Flavia Pugliese, Carla Columbu & Alfredo Scillitani

Authors
  1. Flavia Pugliese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carla Columbu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfredo Scillitani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Flavia Pugliese.

Ethics declarations

Conflitto di interesse

Gli autori Flavia Pugliese, Carla Columbu e Alfredo Scillitani dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pugliese, F., Columbu, C. & Scillitani, A. Gestione clinica del paziente con iperparatiroidismo primario non candidabile alla paratiroidectomia. L'Endocrinologo 22 (Suppl 1), 64–67 (2021). https://doi.org/10.1007/s40619-021-00897-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-021-00897-2

Search

Navigation